Alkermes ALKS
Nasdaq · Pharmaceutical Preparations · $7.9BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $1.2B | $1.1B | $1.7B | $1.6B | $1.5B | −5.2% | +5.9% | |
| Cost of Revenue (COGS) | $197.3M | $218.1M | $253.0M | $245.3M | $196.5M | −19.9% | −0.1% | |
| Research & Development (R&D) | $290.9M | $272.7M | $270.8M | $245.3M | $324.0M | +32.1% | +2.7% | |
| Selling, General & Admin (SG&A) | $549.6M | $590.8M | $689.8M | $645.2M | $701.5M | +8.7% | +6.3% | |
| Operating Income (EBIT) | $97.7M | $-6.1M | $414.1M | $420.6M | $254.0M | −39.6% | +27.0% | |
| Interest Expense | $11.2M | $13.0M | $23.0M | $22.6M | $12.3M | −45.6% | +2.3% | |
| Income Tax Expense | $11.3M | $2.0M | $-97.6M | $71.6M | $49.8M | −30.5% | +44.8% | |
| GAAP Net Income | $-48.2M | $-158.3M | $355.8M | $367.1M | $241.7M | −34.2% | — | |
| Diluted EPS | $-0.29 | $-0.97 | $2.10 | $2.17 | $1.43 | −34.1% | — | |
| Diluted Shares | 164.8M | 163.7M | 169.7M | 169.2M | 168.7M | −0.3% | +0.6% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $337.5M | $292.5M | $457.5M | $291.1M | $1.1B | +284.6% | +35.0% | |
| Inventory | $150.3M | $181.4M | $186.4M | $182.9M | $196.6M | +7.5% | +6.9% | |
| Total Current Assets | $1.1B | $1.1B | $1.5B | $1.4B | $1.9B | +36.3% | +16.1% | |
| Total Assets | $2.0B | $2.0B | $2.1B | $2.1B | $2.5B | +21.0% | +5.3% | |
| Total Current Liabilities | $471.3M | $497.7M | $520.2M | $465.2M | $543.4M | +16.8% | +3.6% | |
| Total Debt (Short + Long Term) | $295.8M | $293.3M | $290.7M | $288.8M | $0 | −100.0% | — | |
| Total Liabilities | $911.9M | $920.2M | $933.5M | $590.6M | $667.7M | +13.1% | −7.5% | |
| Stockholders' Equity | $1.1B | $1.0B | $1.2B | $1.5B | $1.8B | +24.2% | +13.1% | |
| Net Cash / (Net Debt) | $41.7M | $-797,000 | $166.7M | $2.3M | $1.1B | +48103.9% | +127.6% | |
| Invested Capital | $1.1B | $1.0B | $1.0B | $1.5B | $699.5M | −52.2% | −10.1% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $101.7M | $21.0M | $401.4M | $439.1M | $520.8M | +18.6% | +50.4% | |
| Depreciation & Amortization (D&A) | $78.7M | $77.9M | $74.9M | $28.5M | $27.2M | −4.8% | −23.3% | |
| Stock-Based Compensation (SBC) | $87.6M | $94.3M | $100.9M | $96.6M | $98.7M | +2.2% | +3.0% | |
| Capital Expenditures (CapEx) | $28.0M | $38.3M | $48.0M | $33.5M | $40.4M | +20.7% | +9.6% | |
| Free Cash Flow (FCF) | $73.7M | $-17.2M | $353.3M | $405.6M | $480.3M | +18.4% | +59.8% | |
| True FCF (ex-SBC Owner Cash) | $-13.9M | $-111.5M | $252.4M | $309.0M | $381.6M | +23.5% | — | |
| Share Repurchases (Buybacks) | — | — | — | $200.3M | $200.3M | +0.0% | +0.0% | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.